Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725634 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Malignant Solid Tumor, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT00725634: Completed Phase 1 study of Multiple Myeloma and Malignant Solid Tumor, sponsored by AVEO Pharmaceuticals.
NCT00725634 is a Phase 1 study of Multiple Myeloma and Malignant Solid Tumor that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 41 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725634, a Phase 1 study of Multiple Myeloma and Malignant Solid Tumor, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the safety, tolerability and DLTs of AV-299 in combination with erlotinib in patients with relapsed or refractory solid tumors.
Primary Outcome
Assessment of any dose-limiting toxicity
Conditions Studied
Interventions
- BIOLOGICAL AV-299
- BIOLOGICAL AV-299 + erlotinib
Study Locations (3)
Arizona
- Investigational Site 2 - Scottsdale
Ohio
- Investigational Site 3 - Columbus
Texas
- Investigational Site 1 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT00725634 record still lists
NCT00725634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which AV-299 is the first listed.
NCT00725634 reports a single indexed study location in Arizona, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT00725634 about?
NCT00725634 is a clinical study titled "A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma". Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the safety, tolerability and DLTs...
What is the current status of trial NCT00725634?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2008-09. Estimated completion is 2013-12.
What conditions does trial NCT00725634 study?
This clinical trial studies the following conditions: Multiple Myeloma, Malignant Solid Tumor, Lymphomas.
What interventions are being tested in trial NCT00725634?
The interventions under investigation include: AV-299 (BIOLOGICAL), AV-299 + erlotinib (BIOLOGICAL).
Who is sponsoring clinical trial NCT00725634?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00725634 being conducted?
This trial has 3 study locations across Arizona, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00725634's enrollment target sits among peer trials
41 285th of 438 higher than 151 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia